Core Curriculum Committee Members
|Philippe E. Spiess, MD, MS|
Dr Philippe Spiess is presently an associate member in the department of Genitourinary Oncology at the Moffitt Cancer Center and Research Institute and associate professor in the department of urology at the University of South Florida. He completed his urology residency at McGill University in Montreal, Canada and then a 3-year urologic oncology fellowship at the University of Texas M. D. Anderson Cancer Center in Houston Texas. Dr Spiess has published over 150 peer reviewed manuscripts and has edited 5 textbooks in urologic oncology. Dr Spiess currently serves as the vice-chair of the NCCN panel on bladder and penile cancer and is on the editorial board of several national and international peer reviewed journal such as Urologic Oncology: Seminars and Original Investigations, International Brazilian Journal of Urology, and BMC Urology.
|Kenneth Ogan, MD|
|Senior Consultant: Calculus, Lap/Robotics, Upper Tract Obstruction|
Dr. Ogan is The Louis McDonald Orr Clinical Professor of Urology at the Emory University School of Medicine and Co-Director of Emory Comprehensive Stone Center.
Dr. Ogan attended the University of Vermont, Burlington, VT for his undergraduate education (Bachelor in Art). He received his medical degree from New York Medical College in Valhalla, New York followed by urology residency training at George Washington University School of Medicine. Dr. Ogan completed his fellowship training in endourology, minimally invasive surgery and laparoscopy at the University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Ogan is a diplomate of the American Board of Urology (2003).
Dr. Ogan clinical and research interests lie in minimally invasive therapy including laparoscopic and robotic urologic oncologic (cancer) surgery. He has pioneered various surgical techniques for laparoscopic, robotic and thermal ablation kidney cancer surgery to cure patients from cancer while preserving their kidney function. Dr. Ogan performs robotic surgery for the treatment of kidney, bladder and prostate cancer. Patients attending Emory Urology for cancer treatment have the unique opportunity to be cured of their disease while at the same time preserve their vital organs, their functionality and quality of life. As co-director of the Stone Clinic, Dr. Ogan is also involved in the prevention and endoscopic/percutaneous management of patients with kidney stones.
Dr. Ogan has lectured both nationally and internationally. He is closely involved in teaching and mentoring medical students, urology residents and post-graduate fellows. His research involves the utilization of innovative virtual reality systems to train surgeons to perform surgical procedures. Dr. Ogan’s innovative work in teaching and training surgeons is well recognized nationally. He is the recipient of the Golden Apple Teaching Award from Emory University Department of Urology in 2008 & 2012. He has authored multiple book chapters and scientific journal articles.
|Jodi Antonelli, MD|
|Senior Editor: Calculus, Lap/Robotics, Upper Tract Obstruction|
Jodi Antonelli, M.D. is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center. She specializes in the medical and surgical management of kidney stone disease. Dr. Antonelli earned her medical degree from Jefferson Medical College of Thomas Jefferson University. She completed a general surgery internship and a urology residency at Duke University Medical Center. She completed a fellowship in endourology and stone disease in the Department of Urology at UT Southwestern. Her research interests include evaluation of dietary and medical therapies for kidney stone prevention, assessment of outcomes for minimally invasive surgical treatments, and development and assessment of surgical innovation. She was the recipient of the 2014 Elisabeth Pickett Research Award for the Society of Women in Urology. Dr. Antonelli is a member of the American Urological Association, the Endourological Society, and ROCK Society.
|Larissa Bresler, MD|
|Senior Consultant: Core/General, Consults & Emergencies, Trauma|
Dr. Bresler MD, DABMA is an Associate Professor of Urology with a joint appointment in the LUMC Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine. She is an AOA graduate of the Oregon Health and Sciences University and completed her Urology Residency at Loyola followed by a formal medical acupuncture training (Helms Medical Institute) achieving a title of DABMA (Diplomate of American Board of Medical Acupuncturea). Since 2016, she has been serving on the board of directors of the American Academy of Medical Acupuncture and a chairperson of their research committee. Dr. Bresler is also a physician scientist with variety of research interests. Her multifaceted interests include male and female pelvic medicine, pain management, bladder dysfunction, and Resident Wellness. She is the recipient of funding from the Industry, the Interstitial Cystitis Association, and is an applicant for NIH and Merit funding from the VA system for her work on the microbiomes of the urinary tract. She is an active participant in the AUA Core Curriculum Committee in a senior editor role of all core topics as well as the team leader and author for anatomy and physiology section. Dr. Bresler was chosen to participate in the 2018-19 AUA leadership program and successfully completed their group leadership project.
|Michael Liss, MD|
|Senior Editor: Core/General, Consults & Emergencies, Trauma|
|Dr. Michael A. Liss MD, MAS is an Assisant Professor at the University of Texas Health Science Center San Antonio specializing in Urologic Oncology. He graduated Magna Cum Laude with a BS in Biology from Benedictine University in Illinois, received his medical degree with honors in research from the Medical College of Wisconsin, and completed his residency at UC Irvine. He then obtained a Masters of Applied Science (M.A.S.) in Clinical Research during his Society of Urologic Oncology approved urologic oncology fellowship at the University of California San Diego. His primary research intrests include incorporating imaging and biomarker translational reserach into interventional clinical trials, surgical education and training, and infection prevention with antibiotic stewarship.|
|Art R. Rastinehad, DO|
|Senior Consultant: Interventional Radiology, Infections, Transplant, Renovascular Diseases|
Art R. Rastinehad D.O., Northwell Health’s System Director for Prostate Cancer at the Cancer Institute, Vice Chair of Urology at Lenox Hill Hospital
Art Rastinehad, D.O. joined the faculty at Northwell Health in January 2020. He is the Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair of Urology at Lenox Hill Hospital. He trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery.
Dr. Rastinehad’s prostate cancer team has now incorporated state-of-the-art imaging to help visualize suspicious areas in the prostate for cancer. Dr. Rastinehad has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principle investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques. Using information from the prostate MRI, we can now target specific areas to better diagnose and quantify a patient’s prostate cancer. This was the first trial of this technology in the United States outside the National Institutes of Health. This new clinical approach is helping to lay a foundation for the evaluation of a new technique, Focal Therapy, which only treats the diseased portion of the prostate. As of May 2016, Dr Rastinehad was the first in the world to perform a gold nano-particle directed ablation using an transperineal MR US Fusion guided focal therapy system. Dr Rastinehad and his team recently published the first series using this new technology in Proceedings of the National Academy of Science (PNAS).
|Soroush Rais-Bahrami, MD|
|Senior Editor: Interventional Radiology, Infections, Transplant, Renovascular Diseases|
Dr. Soroush Rais-Bahrami is an Assistant Professor of Urology and Radiology at the University of Alabama at Birmingham as well as being a co-founder of the UAB Program for Personalized Prostate Cancer Care.
|Alan W. Shindel, MD, MAS|
|Senior Consultant: Sexual Medicine and Andrology|
|Alan W. Shindel, MS MAS, is an Associate Professor of Urology at the University of California, San Francisco (UCSF). He graduated from the school of medicine at Washington University in Saint Louis in 2002. He completed his residency training in urology at Barnes-Jewish Hospital in 2007. After completion of his residency he started a 3-year research and clinical fellowship in andrology (men’s reproductive and sexual health) at UCSF under the direction of Drs. Tom Lue and Ira Sharlip. He joined the faculty of urology at the University of California Davis (UC Davis) in 2010 as an assistant professor of urology; he was promoted to associate professor of urology in 2014. His clinical practice at that time was devoted towards care of patients with sexual concerns, urinary tract symptoms, and chronic pain syndromes. During his time at UC Davis he served in numerous capacities on the medical school admissions committee and was director of the medical student rotations in urology. He was the Inaugural Editor in Chief for Sexual Medicine, an open access journal of the International Society for Sexual Medicine from 2012 to 2015 and served on the board of the Sexual Medicine Society of North America from 2013 to 2015. In 2015 he left UC Davis to serve as a Medical Director at Genomic Health Inc, a manufacturer of genomic based tests for prostate cancer. After two years at Genomic Health Inc. Dr. Shindel returned to UCSF in 2017.|
|Charles Welliver, MD|
|Senior Editor: Sexual Medicine and Andrology|
|Charles Welliver, MD is an Assistant Professor of Surgery in the Division of Urology at Albany Medical College. He is fellowship trained in Andrology with a practice solely focusing on men's health. Dr. Welliver has received awards both regionally and nationally for his research. He has a special interest in erectile dysfunction, Peyronie's disease, optimization of penile prosthetics, factors affecting male fertility and voiding dysfunction in men. He is involved in the American Urologic Association as a member of the Public Media Committee and is a reviewer for multiple journals including the Journal of Urology. He was named Best Reviewer in 2016 for the Journal of Urology for reviews on BPH/Sexual Function/Infertility. He has been a member of the AUA since 2009.|
|Brian F. Chapin, MD|
|Senior Consultant: Oncology, Urinary Diversion, Adrenal|
Dr. Brian Chapin is an Associate Professor, Director of the Urologic Oncology Fellowship and Co-Director of Clinical Research Programs in the Department of Urology at The University of Texas MD Anderson Cancer Center. He provides complete surgical care for men and women diagnosed with urologic malignancies. He performs open surgery and minimally invasive/robotic surgery, for patients with prostate, kidney, bladder and testis cancers. His major clinical focus is on the treatment of high risk- localized, locally advanced and metastatic prostate cancers. He has active clinical research protocols developing the integration of surgical, radiation and medical therapies in the treatment of advanced prostate cancer. Dr. Chapin coordinates grant funded translational research at M.D Anderson, which is attempting to identify the biologic and immunologic changes that occur with surgical and systemic therapy treatments in advanced prostate cancer and how these changes may be exploited with use of integrating local and systemic therapies. Using a comprehensive multimodality approach to this disease, Dr. Chapin’s goal is to ease suffering and prolong survival in men with advanced prostate cancer.
|Sarah P. Psutka, MD, MS|
|Senior Editor: Oncology, Urinary Diversion, Adrenal|
Sarah Psutka MD, MSc is a urologic oncologist and Assistant Professor of Urology at the University of Washington. She received her AB in Biology from Harvard College in 2003 and her MD from Harvard Medical School in 2007. She then completed an internship in General Surgery and Residency in Urology at the Massachusetts General Hospital in 2013. During this time, she completed the Clinical Effectiveness Research Program at the Harvard School of Public Health. She subsequently completed a Society of Urologic Oncology Fellowship in Urologic Oncology at the Mayo Clinic, and concurrently obtained her Masters in Clinical and Translational Science from the Mayo School of Graduate Medical Education in 2015. Following completion of her training, she joined the staff of the John H. Stroger Jr. Hospital of Cook County in Chicago where she served as the Director of Urologic Oncology. During this time, Dr. Psutka also was named Assistant Professor of Urology at the Northwestern Feinberg School of Medicine where she conducted clinical research in Bladder Cancer and taught resident trainees. In 2018, she was recruited to join the faculty of the University of Washington, where she now practices as a Urologic Oncologist. Her clinical practice is focused on the treatment of bladder cancer, renal cell carcinoma, and testis cancer. From a research standpoint, her main area of interest is in the study and development of personalized, comprehensive risk stratification measures in patients with urologic malignancies, particularly bladder cancer. She is focused on developing and validating risk stratification programs that will help patients better choose the optimal therapy for them, with the goal of not only improving personalized oncologic outcomes, but also patient reported outcomes such as quality of life. Specifically, she has expertise in the study of precise measurements of frailty and body composition with a focus on sarcopenia.
|Adam Hittelman, MD|
|Senior Consultant: Pediatrics|
Dr. Adam Hittelman is an Associate Professor of Urology and Pediatrics at Yale School of Medicine. He is the Urology Residency Program Director. His clinical practice is focused on Pediatric Urology and congenital urologic disorders. He is the Director of Pediatric Robotic and Minimally Invasive Surgery, Director of the Pediatric Stone Clinic, as well as Co-Director of the Differences of Sexual Development multidisciplinary programs. He had received his BA at the University of California, Berkeley, and subsequently completed his MD and PhD at the New York University School of Medicine. His research interests include the genetic mechanism of patients with Differences of Sexual Development as well as delivery systems and the role of Botulinum Toxin A in the treatment of bladder disorders.
|Bruce J. Schlomer, MD|
|Senior Editor: Pediatrics|
|Matthew P. Rutman, MD|
|Senior Consultant: Voiding, Female, BPH|
Matthew Rutman, M.D., is the Director of Voiding Dysfunction, Incontinence and Urodynamic Center at New York Presbyterian Hospital/Columbia University Medical Center. He is an Associate Professor of Clinical Urology at Columbia University College of Physicians and Surgeons. He graduated with honors from Emory University and The Chicago Medical School. After completing his residency at William Beaumont Hospital, Dr. Rutman completed a fellowship in female urology, voiding dysfunction, neurourology and urodynamics at the UCLA Medical Center.
Dr. Rutman is board-certified in urology and female pelvic medicine and reconstructive surgery (FMPRS). His practice is limited to male and female voiding dysfunctions including urinary retention, benign prostatic hyperplasia (BPH), interstitial cystitis, prostatitis, urinary incontinence, overactive bladder, neurogenic bladder, urinary tract infections, and reconstructive female urology surgery for vaginal prolapse, urethral diverticulum and vesico-vaginal fistulae. He has authored over 40 book chapters and publications in leading journals and urology textbooks. His clinical and research interests are in male and female incontinence, vaginal prolapse, voiding dysfunction, urodynamics and surgical outcomes.
|Gregory Murphy, MD|
|Senior Editor: Voiding, Female, BPH|
Dr. Murphy went to medical school at the University of Massachusetts. His residency training was at the University of Connecticut followed by a fellowship in GU trauma and reconstruction at UCSF. Dr. Murphy is currently on faculty at Washington University School of Medicine.